Skip to content

Editors

Harry Cassin
Publisher and Editor

Andy Spalding
Senior Editor

Jessica Tillipman
Senior Editor

Richard L. Cassin
Editor at Large

Elizabeth K. Spahn
Editor Emeritus

Cody Worthington
Contributing Editor

Julie DiMauro
Contributing Editor

Thomas Fox
Contributing Editor

Marc Alain Bohn
Contributing Editor

Bill Waite
Contributing Editor

Shruti J. Shah
Contributing Editor

Russell A. Stamets
Contributing Editor

Richard Bistrong
Contributing Editor

Eric Carlson
Contributing Editor

Bill Steinman
Contributing Editor

Giant corporations are good for compliance

Most of us, if we have any sense at all, harbor some healthy distrust of the world’s biggest companies. For good reason we fear the concentrated power of giant corporations. What, after all, is one person compared to the overwhelming might of Facebook, Walmart, or Exxon?… Continue Reading

Supreme Court limits SEC disgorgement power

The U.S. Supreme Court Monday ruled 9-0 to limit the Securities and Exchange Commission’s legal authority to recover ill-gotten profits from defendants.

The Supreme Court in Kokesh v. SEC said the SEC’s use of the remedy known as disgorgement is subject to a five-year statute of limitations.… Continue Reading

Teva announces $519 million FCPA settlement

Teva Pharmaceuticals Industries Ltd. agreed Thursday with the DOJ and SEC to resolve FCPA violations through a deferred prosecution agreement and total payments of $519 million.

The $519 million settlement will rank fourth on our list of the ten biggest FCPA cases.… Continue Reading

Docs collect billions for drug promos

ProPublica ran an exposé this week about big bucks for doctors who promote products for drug companies.

A Nashville psychiatrist led the pack, earning more than $1 million during the past four years for promotional talks and consulting for seven drug companies.… Continue Reading